NCT06491446 - Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

February 28, 2026

Conditions

Human Papillomavirus Infection

Interventions

DRUG

ABI-2280

"Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered."

Trial Locations (16)

Unknown

RECRUITING

PARC Clinical Research, Royal Adelaide Hospital, Adelaide

RECRUITING

Emeritus Research Camberwell, Camberwell

RECRUITING

Holdsworth House Medical Practice, Darlinghurst

RECRUITING

KIMR, Nedlands

NOT_YET_RECRUITING

The Royal Women's Hospital, Parkville

RECRUITING

Emeritus Research Sydney, Sydney

RECRUITING

AusTrials Taringa, Taringa

RECRUITING

AusTrials Wellers Hill, Tarragindi

RECRUITING

Waitemata Clinical Research Ltd, Birkenhead

RECRUITING

P3 Research Dunedin, Dunedin

RECRUITING

P3 Research Hawke's Bay, Hastings

RECRUITING

P3 Research Lower Hutt, Lower Hutt

RECRUITING

Pacific Clinical Trials Network - Tasman, Nelson

RECRUITING

P3 Research Kapiti, Paraparaumu

RECRUITING

Lakeland Clinical Trials, Rotorua

RECRUITING

Clinical Horizons New Zealand, Tauranga